If you’re an active trader or looking for stock market news today, this is probably the one-millionth headline you’ve read with the phrase “Recession Begins” in the title. Apologies for that, but it’s true; we’re officially in a technical recession. For those unfamiliar with the definition of a recession, it’s two consecutive quarters of negative GDP growth.
Today’s second quarter GDP data showed that Q2’s gross domestic product fell 0.9%. This came after the first quarter’s contraction of 1.6% and a staunch difference from how the year ended in 2021. With the definition of recession being met, some may find it interesting that markets aren’t completely failing. That’s likely because of a tighter labor market and that consumers are still spending. Nevertheless, the point is that (for now) recession isn’t scaring the stock market today.
Better yet, there is still somewhat of a risk-on appetite for things like penny stocks. Today we look at the biotech sector for some of the hot stocks to watch today. While the overall biotech market is trending lower, small- and micro-cap stocks are giving some reprieve at the moment.
Biotech Penny Stocks To Watch
- Comera Life Sciences Holdings (NASDAQ: CMRA)
- Athersys, Inc. (NASDAQ: ATHX)
- InflaRx N.V. (NASDAQ: IFRX)
- Revelation Biosciences Inc. (NASDAQ: REVB)
- Chimerix (NASDAQ: CMRX)
Comera Life Sciences Holdings (NASDAQ: CMRA)
Comera Life Sciences is one of the penny stocks to watch as shares have steadily risen this week. The company specializes in transitioning IV medicines to subcutaneous forms and provides patients with self-injectable care.
Earlier this month, Comera announced preclinical topline safety results of its SQore excipient platform.
“The results of this preclinical study provide supportive evidence of the safety of Comera’s lead caffeine-based SQore™ excipient when administered as a subcutaneous (SQ) biologic drug product formulation with a monoclonal antibody (mAb).”
While the headline came out on the 13th, momentum has begun to flow this week. A more extensive study, SEQURUS-2, has already started to provide a “statistically robust evaluation” of caffeine on the PK of SQ-administered ipilimumab. Topline study results will be presented at the 14th Annual Bioprocessing Summit in mid-August. So the clock has begun ticking, and CMRA stock continues hitting new July highs.
Athersys, Inc. (NASDAQ: ATHX)
The exciting thing about penny stocks is that you can have one that slides for months, hits new 52-week lows, then seemingly out of nowhere, explodes. That is the case with Athersys in the stock market today. Shares of ATHX stock recently tested fresh lows on Tuesday but have bounced back nearly 100%.
What’s going on with Athersys? This week the company announced its next round of financial results. August 11th, after the close, is the time to mark down if ATHX stock is on your radar. The company is developing its MultiStem cell therapy product for neurological, inflammatory, immune, and cardiovascular indications. Several trials are currently ongoing evaluating its regenerative potential.
In the most recent Key Opinion Leader panel events, Athersys discussed its TREASURE study studying MultiStem for ischemic stroke. With the upcoming event in August, eyes could be on ATHX stock in hopes of new data or guidance on its pipeline.
InflaRx N.V. (NASDAQ: IFRX)
Is InflaRX on your penny stocks list today? If so, you probably saw headlines earlier in the week regarding an Emergency Use Authorization application announced for its vilobelimab. The company reported plans for the EUA application for using its candidate to treat critically ill COVID-19 patients. The move came after encouraging FDA interactions were held in a Type B meeting.
“Our constructive interactions with the FDA and the helpful guidance they provided have encouraged us to move forward with applying for EUA for vilobelimab in critically ill COVID-19 patients,” said Prof. Niels C. Riedemann, CEO and Founder of InflaRx in this week’s update.
Vilobelimab also received FDA Fast Track designation in treating ulcerative pyoderma gangrenosum. The skin disorder is being studied after the application of the drug candidate. With multiple use cases, new designations, and current studies in process and planned, there could be several things to follow with IFRX stock.
Revelation Biosciences Inc. (NASDAQ: REVB)
Shares of REVB stock popped late in the week this week, thanks to a turnaround in sentiment. Revelation specializes in immunologic-based therapies and recently announced a $5 million offering to push the ball down the field with the development of its REVTx-99b, REVTx-200, and REVTx-300 treatment platforms.
Since the offering is expected to close today, REVB stock is back in focus with new cash in hand. Its lead candidate, REVTx-99b, recently completed the dosing of its Phase 1b CLEAR clinical study. In a mid-June update, James Rolke, Chief Executive Officer of Revelation, explained, “We are excited to complete enrollment in this study and look forward to reporting the results in the third quarter of 2022.”
In true fashion, the company reported this data on July 22nd after the closing bell. The primary endpoint to evaluate the effects of REVTx-99b versus placebo on safety and tolerability was met. Now the plan is to assess the treatment candidate further.
Chimerix (NASDAQ: CMRX)
Monkeypox stocks are still heating up the newsfeeds in the stock market today. Following earlier reports that the WHO declared the monkeypox spread a Global Health Emergency, this basket of biotech stocks has flourished in recent weeks. Led by the likes of Siga Technologies (NASDAQ: SIGA), plenty of cheaper stocks with a monkeypox treatment platform are gaining steam.
Emergent BioSolutions Inc. (NYSE: EBS), another monkeypox stock to watch, bought exclusive worldwide rights to Chimerix’s Tembexa. In a May update, Paul Williams, SVP government/MCM business at Emergent, said, “This transaction expands and further diversifies our medical countermeasures business with the addition of a small molecule therapeutic that aligns with the government’s smallpox preparedness strategy.”
With exposure to the latest monkeypox trend, CMRX is one of the penny stocks to watch. Keep in mind that since many of these companies are moving on speculation and broad headlines, sentiment and price movement, for that matter, can quickly change.